Bioprinting Strategies

The agonizing and scarring process of traditional skin grafting for burn victims is being rendered obsolete by the convergence of robotics and regenerative medicine. 🩹 Researchers at the Wake Forest Institute for Regenerative Medicine in the United States have successfully advanced their mobile, in-situ 3D skin bioprinter into highly successful clinical applications. Instead of harvesting large, painful sections of healthy skin from elsewhere on a patient’s body, this specialized machine literally prints a customized layer of new living tissue directly onto the injury. The device resembles a highly sophisticated, multi-axis robotic arm mounted on a cart that can be rolled right up to a hospital bed. The machine first uses an integrated laser scanner to map the exact topography, depth, and size of the wound with microscopic accuracy. Once the geometry is mapped, the printer utilizes a sterile "bio-ink" consisting of the patient's own isolated skin cells suspended in a healing hydrogel, depositing them layer by layer precisely where they are needed to replicate the dermis and epidermis. In early 2026, this technology has demonstrated a profound ability to accelerate the healing process of severe, extensive burns while virtually eliminating donor-site morbidity and scarring. By combining digital 3D mapping with living biological material, this breakthrough allows the human body to regenerate its largest organ smoothly, setting a new global standard for trauma care. - News Source: Science Translational Medicine / Wake Forest – "In-Situ 3D Bioprinter Demonstrates Rapid Healing in Clinical Burn Trauma Applications" (2025/2026) -

We developed not only a new 3D bioprinting platform that can create many tiny, cell-containing tissue models at once, but also a system in which these hydrogels remain fully immersed in compartmentalized droplets after printing—reducing both fabrication and application time from hours to minutes. Sequential fabrication remains a major bottleneck in scaling 3D bioprinting for disease modeling and drug discovery, forcing a trade‑off between physiological relevance and throughput. In our new Advanced Functional Materials paper, we introduce a platform for fully parallel 3D bioprinting of cell‑laden hydrogel arrays on a wall‑less liquid compartmentalization system. By integrating DLP stereolithography with a slippery liquid‑infused Droplet Microarray (SLIPS‑DMA), fabrication time is decoupled from array size. Tens to hundreds of cell‑containing 3D hydrogel constructs with defined geometries can be printed simultaneously, in minutes, fully immersed in compartmentalized droplets while preserving shape fidelity and cell viability. This establishes a scalable system‑on‑a‑chip for multiplexed screening of cell–material–drug interactions, overcoming a long‑standing throughput limitation in 3D biofabrication. Paper: https://lnkd.in/exfM4tcy

🚨 What If Surgeons Became Obsolete? Scientists at Caltech just 3D-printed inside a living body — without cutting the skin. And it’s not sci-fi anymore. Forget scalpels. Forget long hospital stays. This is bioprinting through sound waves — real structures formed deep inside living tissue using focused ultrasound. Here’s what’s actually happening: • Researchers inject a liquid bio-ink into the body — loaded with temperature-sensitive carriers that release crosslinking molecules only when ultrasound heats them slightly. • A focused ultrasound beam raises the temperature by just a few degrees — triggering the ink to solidify into a polymer or hydrogel exactly where needed. • The process is guided and monitored in real time using ultrasound imaging — no incisions, no internal cameras. So far, scientists have successfully printed: ✔ Polymer structures for drug delivery and wound sealing ✔ Hydrogels that could one day become tissues or scaffolds inside organs ✔ Even bioelectric materials for sensing internal physiology — all without surgery. 🔥 Here’s the provocative part: If we can manufacture structures inside a beating heart or damaged liver without surgery, what happens to: ➡ Traditional surgery? ➡ Surgical training pathways? ➡ The entire multimillion-dollar implant industry? This is NOT future talk — it’s real research published in Science and led by engineers who used ultrasound the way others use a printer nozzle. 🎯 Discussion Starter: Where do YOU think this technology will hit first — cancer therapy? Organ repair? Replacing pacemakers? Or printed nerve networks? 👇 Drop your boldest prediction. 📚 Sources • California Institute of Technology (Caltech) – 3D Printing In Vivo Using Sound • IEEE Spectrum – Bioprinting Inside the Body Using Ultrasound • Nature Materials (research publication referenced by Caltech)

Announcing our latest publication from the #Heilshorn_Biomaterial_Lab! In our new collaborative work, led by brilliant Betty Cai and supervised by Sarah Heilshorn and Sungchul Shin, we developed an integrated fabrication and #endothelialization strategy that directly generates branched, endothelial cell-lined networks using a #diffusion_based, embedded 3D #bioprinting process for the first time. This #innovation not only addresses long-standing challenges in #vascular biofabrication, such as cell uniformity, seeding efficiency, and multi-cell type #patterning but also paves the way for engineering more complex, multi-cellular vasculature. Learn more about how we patterned both #arterial and #venous endothelial cells within a single network to enhance geometric complexity and #phenotypic heterogeneity by reading the full article via the link below: https://lnkd.in/gdcv-hW3 Betty Cai, David Kilian, Julien Roth, Alexis Seymour, Lucia Brunel, Daniel Ramos, @Ricardo J Rios, @Isabella M Szabo, Sean Chryz Iranzo, @Andy Perez, Ram Rao MD PhD, Sungchul Shin, Sarah Heilshorn Stanford University, DTU Health Tech, University of Washington, Seoul National University #Biofabrication #3DBioprinting #TissueEngineering #Bioprinting #VascularEngineering #Endothelialization #Biomaterials #RegenerativeMedicine #BiomedicalEngineering #Innovation #ScientificResearch #CellBiology #VascularNetworks #AdvancedManufacturing #MedicalInnovation #DiffusionBased #EmbeddedBioprinting #MultiCellularSystems #MaterialsEngineering #FutureOfMedicine #Arterial #Venous #ScienceInnovation #HealthcareInnovation #BiomedicalResearch #ScientificPublication

🦾 MedTech Frontiers ⚙️ 3D Bioprinting: From Tissue Models to Implants 3D bioprinting is one of the most exciting technologies in healthcare. And one of the most misunderstood. Many people imagine a future where hospitals simply "print" replacement organs on demand. The reality is both more impressive and more challenging. Today, 3D bioprinting is already enabling: 👉 patient-specific tissue models 👉 advanced drug testing platforms 👉 tumor microenvironment models 👉 regenerative scaffolds for tissue repair The technology has evolved far beyond printing plastic structures. Modern bioprinting combines: 👉 living cells 👉 biomaterials (bioinks) 👉 growth factors 👉 sophisticated scaffold architectures But one major challenge remains: 🩸 Vascularization. Printing cells is difficult. Keeping billions of cells alive after printing is even harder. Without functional blood vessel networks: 👉 oxygen delivery is limited 👉 nutrient transport fails 👉 tissue viability decreases rapidly This is why printing simple tissues is already possible, while printing fully functional organs remains one of the grand challenges of biomedical engineering. Yet progress is accelerating. Researchers are now developing: 👉 cell-laden bioinks 👉 microvascular networks 👉 bioprinted skin, cartilage, and bone constructs 👉 implantable regenerative tissues The question is no longer whether bioprinting will impact medicine. The question is how quickly we can bridge the gap between laboratory constructs and clinically functional tissues. 💡 Take-home message: 3D bioprinting is not about printing organs tomorrow. It's about building the biological infrastructure that could make regenerative medicine fundamentally different within the next decade. #MedTechFrontiers #3DBioprinting #MedTech #RegenerativeMedicine #TissueEngineering #BiomedicalEngineering #HealthcareInnovation #PNTB #Betthera

What if we could print a replacement heart using your own cells? Scientists are getting closer to making this real. Researchers successfully bioprinted a functional rat aorta using living cells and implanted it into rats, where it integrated with native vasculature and showed physiological behavior matching a natural vessel. This was published in Scientific Reports in April 2025. The breakthrough that's making this possible? Advanced bioprinting techniques can now fabricate complex cardiovascular structures including vascular patches, ventricle-like heart pumps, and perfusable vascular networks that closely resemble native blood vessels. For years, the biggest challenge has been vascularization – creating blood vessel networks inside printed tissue. Without proper blood vessels, bioprinted tissues can't get oxygen and nutrients, limiting their size and clinical usefulness. Technologies like digital light processing and stereolithography now enable printing of microscale vascular architectures with extremely high resolution, though they remain largely confined to preclinical proof-of-concept studies. Despite significant research progress, clinical translation remains a challenge – regulatory approval requires extensive preclinical and clinical trials with different standards worldwide. We're not printing replacement organs yet. But we're printing functional blood vessels that work in living animals. That's not just progress. That's a foundation. #bioprinting #tissueengineering #regenerative #medicine #healthcare #medicalinnovation

🧬🖨️ Bioprinting a functional pancreas to fight diabetes — and it's working. @Rousselot, a 130-year-old collagen biomaterials company, is proving that deep materials science expertise is a critical and often overlooked enabler of the bioprinting revolution. Their latest milestone comes through the EU-backed ENLIGHT project: a pan-European consortium with a bold goal of bioprinting a functional pancreatic model to transform how we discover and test diabetes drugs. Key technologies & breakthroughs: 🔬 Gelatin-based bioinks (X-Pure®) — Rousselot developed a hydrogel with tunable mechanical properties to recreate the pancreatic microenvironment, creating a "library" of gelatins and GelMA variants, including a single-component suspension medium that supports extrusion inside a volumetric printing bath — without temperature control — remaining stable for several hours ⚡ Volumetric bioprinting — unlike conventional 3D printers, which take an hour, this volumetric bioprinter produces results within a minute — critical because cell survival rates decrease rapidly over time 🧫 Living tissue that lasts — the ENLIGHT researchers successfully bioprinted pancreatic cell-laden gels that remained viable over 21 days of culture 🧪 iPSC-powered personalization — the ultimate goal involves using a patient's own induced pluripotent stem cells (iPSCs) to build patient-specific tissue for precision drug testing The ENLIGHT consortium includes UMC Utrecht, ETH Zürich, EPFL, AstraZeneca, University of Naples Federico II, and bioprinting company Readily3D — backed by €3.6 million from the European Innovation Fund. 📄 🔗 https://lnkd.in/gzWbMVmj #Bioprinting #3DBioprinting #RegenerativeMedicine #DrugDiscovery #Diabetes #PancreaticResearch #Bioink #LifeSciences #MedTech #TissueEngineering #ENLIGHT #Rousselot #VolumetricBioprinting #PrecisionMedicine #Innovation

I am very happy to share that our most recent paper titled "Advanced bioprinting strategies for fabrication of biomimetic tissues and organs" published by the International Journal of Extreme Manufacturing is available online (https://lnkd.in/dZfHBuWf). This paper discusses the challenges and design requirements in the fabrication of 3D biomimetic tissue constructs, emphasising the need for advanced bioprinting strategies. The focus is on achieving biomimicry, including 3D anatomically relevant structures, biomimetic microenvironments, and vascularisation. Various advanced bioprinting strategies are discussed in detail, including advancements in both fabrication techniques and bio-inks. Future directions in advanced bioprinting systems are outlined, with special attention to multi-modal bioprinting systems, in-situ bioprinting, and the integration of machine learning into bioprinting processes. The critical role of bio-inks and printing methodologies in influencing cell viability is highlighted, providing insights into strategies for enhancing cellular functionality throughout the bioprinting process. The paper also addresses considerations post-fabrication, particularly in accelerating tissue maturation, as a pivotal component for advancing the clinical applicability of bioprinted tissues. The paper navigates through the challenges, innovations, and prospects of advanced bioprinting strategies, highlighting their transformative impact on tissue engineering. Thank you to all co-authors Ng Wei Long, Cian Vyas, BOYANG HUANG, Wai Yee Yeong 👏 ➡️ I hope you enjoy reading the paper! #3dbioprinting; #insituprinting; #bioinks; #biomimicry; #vascularisation; #cells; #tissueengineering

A remarkable step forward for 3D bioprinting and vascular disease modeling has just been published by Professor Yi-Chin Toh and her group! The study introduces a patient-specific 3D printed carotid artery model that uniquely integrates anatomical geometry, hemodynamic validation, and biological responses of vascular cells. Using DLP bioprinting with CELLINK LUMEN X, the researchers successfully recreated physiological shear stress conditions and demonstrated endothelial alignment and monocyte adhesion in disturbed flow regions, which are critical mechanisms in atherosclerosis. This work demonstrates how 3D bioprinting can unite structure, flow, and biology into one high-fidelity model. It provides a powerful new platform for studying the mechanisms of vascular disease and represents a significant step toward precision medicine. With this foundation, future directions may include incorporating pulsatile flow, fluid–structure interaction, and broader patient-specific modeling. Such advances could transform how we study and ultimately treat cardiovascular disease. Congratulations Professor Yi-Chin Toh and her team for this tremendous achievement!! Full paper: “A Patient-Specific 3D Printed Carotid Artery Model Integrating Vascular Structure, Flow, and Endothelium Responses” Advanced Healthcare Materials, 2025 https://lnkd.in/d4t-t7Y8 3Dバイオプリンティングと血管疾患モデル研究における画期的な成果が Advanced Healthcare Materials に発表されました。 この研究では、患者特異的な3Dプリント頸動脈モデルを構築し、解剖学的形状、血行動態の検証、血管細胞の生物学的応答を一体的に統合することに成功しました。CELLINK LUMEN X を用いたDLPバイオプリンティングによって、生理的なせん断応力環境を再現し、内皮細胞の整列や乱流部位での単球接着といった動脈硬化に関連する重要な現象を明確に示しています。 この研究は、形態・流れ・生物学を統合した高精度モデルを提示し、血管疾患の発症メカニズム解明に大きな可能性を示しました。さらに、精密医療の実現に向けた重要な一歩となります。 CELLINK QUT (Queensland University of Technology) BICO　#Bioprinting #DLP #MPS